Changeflow GovPing Healthcare & Life Sciences Kyoto University Patent for Regulatory T Cell P...
Routine Rule Added Final

Kyoto University Patent for Regulatory T Cell Production Method

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

Kyoto University published patent application US20260109949A1 on April 23, 2026, covering a method for producing regulatory T cells by culturing CD4+ T cells derived from pluripotent stem cells in the presence of IL-4 and a TGF-βR agonist. The application lists Shin KANEKO, Shoichi IRIGUCHI, Takayuki SATO, and Yoshiaki KASSAI as inventors. The disclosed invention also encompasses the resulting cell population containing proliferated regulatory T cells and a medicine containing that cell population.

“Disclosed are a method for producing a cell population in which regulatory T cells have proliferated, including (1) culturing a cell population containing CD4+ T cells derived from pluripotent stem cells in the presence of IL-4 and a TGF-βR agonist, a cell population containing regulatory T cells obtained according to the method, and a medicine containing the cell population containing regulatory T cells.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 227 changes logged to date.

What changed

The USPTO published patent application US20260109949A1 for Kyoto University on April 23, 2026. The application discloses a method for proliferating regulatory T cells involving culturing CD4+ T cells from pluripotent stem cells with IL-4 and a TGF-beta receptor agonist. The patent also covers the cell population obtained by this method and pharmaceutical compositions containing those regulatory T cells.

For entities in biotechnology research and cell therapy development, this published application establishes Kyoto University's intellectual property rights in T cell expansion methodology. Research institutions and biotech companies developing pluripotent stem cell-derived T cell therapies should review this disclosure for potential licensing considerations or to assess freedom-to-operate for competing programs.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

T CELL PRODUCTION METHOD

Application US20260109949A1 Kind: A1 Apr 23, 2026

Assignee

Kyoto University

Inventors

Shin KANEKO, Shoichi IRIGUCHI, Takayuki SATO, Yoshiaki KASSAI

Abstract

Disclosed are a method for producing a cell population in which regulatory T cells have proliferated, including (1) culturing a cell population containing CD4+ T cells derived from pluripotent stem cells in the presence of IL-4 and a TGF-βR agonist, a cell population containing regulatory T cells obtained according to the method, and a medicine containing the cell population containing regulatory T cells.

CPC Classifications

C12N 5/0637 A61K 35/17 A61K 40/11 A61P 37/06 C12N 5/10 C12N 2501/15 C12N 2501/2302 C12N 2501/2303 C12N 2501/2304 C12N 2501/2333 C12N 2501/25 C12N 2506/45 C12N 2510/00

Filing Date

2023-09-25

Application No.

19114947

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US20260109949A1

Who this affects

Applies to
Educational institutions
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biotechnology research Cell therapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!